Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Return on Sales (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Return on Sales for 8 consecutive years, with 7.17% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 543.0% to 7.17% in Q3 2025 year-over-year; TTM through Sep 2025 was 7.17%, a 471.0% decrease, with the full-year FY2024 number at 2.45%, up 25.0% from a year prior.
  • Return on Sales was 7.17% for Q3 2025 at Whitehawk Therapeutics, down from 4.54% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 934.21% in Q3 2021 to a low of 45.63% in Q1 2021.
  • A 5-year average of 44.33% and a median of 2.66% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 93455bps in 2021, then crashed -93762bps in 2022.
  • Whitehawk Therapeutics' Return on Sales stood at 1.14% in 2021, then tumbled by -133bps to 2.66% in 2022, then increased by 3bps to 2.57% in 2023, then rose by 2bps to 2.52% in 2024, then crashed by -184bps to 7.17% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Return on Sales are 7.17% (Q3 2025), 4.54% (Q2 2025), and 2.02% (Q1 2025).